For serine/threonine kinase 11-deficient non-small cell lung cancer (NSCLC) cells, erlotinib suppresses growth and induces apoptosis through the activation of adenosine monophosphate-activated protein kinase (AMPK) and suppression of the mammalian target of rapamycin (mTOR) signaling, due to increased ROS and associated mitochondrial damage [18]. Here, STK11 is linked to non-small cell lung carcinoma.